|
1.
|
|
16 p, 2.7 MB |
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
/
Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ;
Brasó-Maristany, Fara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Martínez-Sáez, Olga (Universitat de Barcelona) ;
Sanfeliu, Esther (Hospital Clínic i Provincial de Barcelona) ;
Bellet, Meritxell (Vall d'Hebron Institut d'Oncologia) ;
Galván, Patricia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Martínez, Débora (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Pascual, Tomás (University of North Carolina) ;
Marín-Aguilera, Mercedes (Reveal Genomics (Barcelona)) ;
Rodríguez, Anna (Hospital Clínic i Provincial de Barcelona) ;
Chic, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Adamo, Barbara (Universitat de Barcelona) ;
Paré Brunet, Laia (Reveal Genomics (Barcelona)) ;
Vidal Losada, Maria (Universitat de Barcelona) ;
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ballana, Ester (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gómez-Rey, Marina (Vall d'Hebron Institut d'Oncologia) ;
Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ;
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Matito, Judit (Vall d'Hebron Institut d'Oncologia) ;
Sánchez-Bayona, Rodrigo (Hospital Universitario 12 de Octubre (Madrid)) ;
Suñol, Anna (Vall d'Hebron Institut d'Oncologia) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Ciruelos, Eva (Hospital Universitario 12 de Octubre (Madrid)) ;
Tolosa, Pablo (Hospital Universitario 12 de Octubre (Madrid)) ;
Muñoz, Montserrat (SOLTI cooperative group (Barcelona)) ;
González-Farré, Blanca (Hospital Clínic i Provincial de Barcelona) ;
Villagrasa, Patricia (Reveal Genomics (Barcelona)) ;
Parker, Joel S. (University of North Carolina) ;
Perou, Charles M. (University of North Carolina) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Liquid biopsy has proven valuable in identifying individual genetic alterations; however, the ability of plasma ctDNA to capture complex tumor phenotypes with clinical value is unknown. To address this question, we have performed 0. [...]
2023 -  10.1038/s41467-023-36801-9
Nature communications, Vol. 14 (march 2023)
|
|
|
2.
|
|
11 p, 6.7 MB |
Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease
/
Isola, Ignacio (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Brasó-Maristany, Fara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Moreno, David F. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Mena, Mari Pau (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Oliver-Caldés, Aina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Paré, Laia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rodríguez Lobato, Luis Gerardo (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Martín-Antonio, B (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Cibeira, Maria Teresa (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Lozano, Ester (Universitat de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia) ;
Fernández de Larrea, Carlos (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Background: We previously reported algorithms based on clinical parameters and plasma cell characteristics to identify patients with smoldering multiple myeloma (SMM) with higher risk of progressing who could benefit from early treatment. [...]
2021 - 10.3389/fimmu.2021.792609
Frontiers in immunology, Vol. 12 (22 2021) , p. 792609
|
|
|
3.
|
|
18 p, 1.6 MB |
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
/
Adam-Artigues, Anna (Instituto de Investigación Sanitaria INCLIVA (Valèna, Comunitat Valenciana)) ;
Arenas, Enrique J (Centro de Investigación Biomédica en Red de Cáncer) ;
Martínez-Sabadell, Alex (Vall d'Hebron Institut d'Oncologia) ;
Brasó-Maristany, Fara (Hospital Clínic i Provincial de Barcelona) ;
Cervera Vidal, Raimundo (Instituto de Investigación Sanitaria INCLIVA (Valèna, Comunitat Valenciana)) ;
Tormo, Eduardo (Centro de Investigación Biomédica en Red de Cáncer) ;
Hernando Davalillo, Cristina (Hospital Clínic i Provincial de Barcelona) ;
Martínez Martínez, María Teresa (Hospital Clínic i Provincial de Barcelona) ;
Carbonell Asins, Juan Antonio (Instituto de Investigación Sanitaria INCLIVA (Valèna, Comunitat Valenciana)) ;
Simón, Soraya (Hospital Clínic i Provincial de Barcelona) ;
Poveda Ferriols, Jesús Manuel (Hospital Clínic i Provincial de Barcelona) ;
Moragón, Santiago (Hospital Clínic i Provincial de Barcelona) ;
Zazo, Sandra (IIS Fundación Jiménez Díaz. Department of Pathology) ;
Martínez, Débora (Hospital Clínic i Provincial de Barcelona) ;
Rovira, Ana (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Burgués, Octavio (Hospital Clínic i Provincial de Barcelona) ;
Rojo, Federico (IIS Fundación Jiménez Díaz. Department of Pathology) ;
Albanell Mestres, Joan (Universitat Pompeu Fabra) ;
Bermejo, Begoña (Hospital Clínic i Provincial de Barcelona) ;
Lluch, Ana (Universitat de València. Departament de Medicina) ;
Prat, Aleix (SOLTI Breast Cancer Research Group) ;
Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Eroles, Pilar (Universitat de València. Departament de Fisiologia) ;
Cejalvo, Juan Miguel (Hospital Clínic i Provincial de Barcelona)
Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of trastuzumab resistance. [...]
2022 - 10.1126/sciadv.abk2746
Science advances, Vol. 8, Issue 20 (May 2022) , art. eabk2746
|
|
|
4.
|
|
14 p, 502.9 KB |
Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe
/
Pinato, David J. (Imperial College London. Department of Surgery & Cancer) ;
Lee, Alvin J. X. (University College London Hospitals) ;
Biello, Federica (University of Piemonte Orientale) ;
Seguí, Elia (Hospital Clínic i Provincial de Barcelona) ;
Aguilar-Company, Juan (Hospital Universitari Vall d'Hebron) ;
Carbó, Anna (Hospital Universitari de Girona Doctor Josep Trueta) ;
Bruna, Riccardo (University of Piemonte Orientale) ;
Bower, Mark (Chelsea & Westminster Hospital) ;
Rizzo, Gianpiero (Fondazione IRCCS Policlinico San Matteo) ;
Benafif, Sarah (University College London Hospitals) ;
Carmona, Carme (Hospital Universitari de Girona Doctor Josep Trueta) ;
Chopra, Neha (University College London Hospitals) ;
Cruz, Claudia Andrea (Hospital Clínic i Provincial de Barcelona) ;
D'avanzo, Francesca (University of Piemonte Orientale) ;
Evans, Joanne S. (Imperial College London) ;
Galazi, Myria (University College London Hospitals) ;
Garcia-Fructuoso, Isabel (Hospital Universitari de Girona Doctor Josep Trueta) ;
Pria, Alessia D. (Chelsea & Westminster Hospital) ;
Newsom-Davis, Thomas (Chelsea & Westminster Hospital) ;
Ottaviani, Diego (University College London Hospitals) ;
Patriarca, Andrea (University of Piemonte Orientale) ;
Reyes, Roxana (Hospital Clínic i Provincial de Barcelona) ;
Sharkey, Rachel (University of Piemonte Orientale) ;
Sng, Christopher C. T. (University College London Hospitals) ;
Wong, Yien Ning Sophia (University College London Hospitals) ;
Ferrante, Daniela (University of Piemonte Orientale) ;
Scotti, Lorenza (University of Piemonte Orientale) ;
Avanzi, Gian Carlo (University of Piemonte Orientale) ;
Bellan, Mattia (University of Piemonte Orientale) ;
Castello, Luigi Mario (University of Piemonte Orientale) ;
Marco-Hernández, Javier (Hospital Clínic i Provincial de Barcelona) ;
Mollà, Meritxell (Hospital Clínic i Provincial de Barcelona) ;
Pirisi, Mario (University of Piemonte Orientale) ;
Ruiz-Camps, Isabel (Hospital Universitari Vall d'Hebron) ;
Sainaghi, Pier Paolo (University of Piemonte Orientale) ;
Gaidano, Gianluca (University of Piemonte Orientale) ;
Brunet, Joan (Hospital Universitari de Girona Doctor Josep Trueta) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gennari, Alessandra (University of Piemonte Orientale) ;
Universitat Autònoma de Barcelona
We describe the outcomes in cancer patients during the initial outbreak of the COVID-19 in Europe from the retrospective, multi-center observational OnCovid study. We identified 204 cancer patients from eight centers in the United Kingdom, Italy, and Spain aged > 18 (mean = 69) and diagnosed with COVID-19 between February 26th and April 1st, 2020. [...]
2020 - 10.3390/cancers12071841
Cancers, Vol. 12 Núm. 7 (july 2020) , p. 1-13
|
|
|
5.
|
|
10 p, 1.3 MB |
Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy
/
Floros, Konstantinos V. (Philips Institute for Oral Health Research) ;
Lochmann, Timothy L. (Philips Institute for Oral Health Research) ;
Hu, Bin (Virginia Commonwealth University School of Medicine) ;
Monterrubio, Carles (Memorial Sloan Kettering Cancer Center) ;
Hughes, Mark T. (Philips Institute for Oral Health Research) ;
Wells, Jason D. (Norris Cotton Cancer Center) ;
Bernadó Morales, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Ghotra, Maninderjit S. (Philips Institute for Oral Health Research) ;
Costa, Carlotta (Massachusetts General Hospital (Boston)) ;
Souers, Andrew J. (AbbVie Inc) ;
Boikos, Sosipatros A. (Virginia Commonwealth University) ;
Leverson, Joel D. (AbbVie Inc) ;
Tan, Ming (University of South Alabama) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ;
Koblinski, Jennifer E. (Virginia Commonwealth University School of Medicine) ;
Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Paré Brunet, Laia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Miller, Todd W. (Norris Cotton Cancer Center) ;
Dozmorov, Mikhail G. (Virginia Commonwealth University) ;
Harada, Hisashi (Philips Institute for Oral Health Research) ;
Windle, Brad E. (Philips Institute for Oral Health Research) ;
Scaltriti, Maurizio (Memorial Sloan Kettering Cancer Center) ;
Faber, Anthony C. (Philips Institute for Oral Health Research)
In HER2 -amplified breast cancers, HER2 inhibitors have been very successful as adjuvant therapy but not as monotherapy. Here, we demonstrate that coamplification of a HER2 intronic miRNA causes intrinsic resistance to HER2 inhibitors by indirectly down-regulating the pro-apoptotic NOXA. [...]
2018 - 10.1073/pnas.1717820115
Proceedings of the National Academy of Sciences of the United States of America, Vol. 115 (february 2018) , p. E2594-E2603
|
|
|
6.
|
|
14 p, 2.2 MB |
Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer
/
Aguado, Cristina (Quirón Dexeus University Hospital) ;
Teixidó, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Román, Ruth (Quirón Dexeus University Hospital) ;
Reyes, Roxana (Hospital Clínic i Provincial de Barcelona) ;
Giménez-Capitán, Ana (Quirón Dexeus University Hospital) ;
Marin, Elba (Hospital Clínic i Provincial de Barcelona) ;
Cabrera, Carlos (Grup Quirónsalud (Barcelona, Catalunya)) ;
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Castillo, Sergi (Hospital General de Granollers) ;
Muñoz, Silvia (Hospital General de Granollers) ;
Arcocha, Ainara (Hospital Clínic i Provincial de Barcelona) ;
López-Vilaró, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Aldeguer, Erika (Quirón Dexeus University Hospital) ;
Rodríguez, Sonia (Quirón Dexeus University Hospital) ;
Moya, Irene (Grup Quirónsalud (Barcelona, Catalunya)) ;
Viteri, Santiago (Quiron Salud Group) ;
Cardona Zorrilla, Andrés Felipe (Clínica del Country) ;
Palmero, Ramon (L'Hospitalet) ;
Sainz, Cristina (Centro de Investigación Biomédica en Red de Cáncer) ;
Mesa-Guzmán, Miguel (Universidad Pública de Navarra) ;
Lozano, Maria D. (Universidad Pública de Navarra) ;
Aguilar-Hernández, Andrés (Grup Quirónsalud (Barcelona, Catalunya)) ;
Martínez-Bueno, Alejandro (Grup Quirónsalud (Barcelona, Catalunya)) ;
González-Cao, María (Grup Quirónsalud (Barcelona, Catalunya)) ;
Gonzalvo, Elena (Hospital Clínic i Provincial de Barcelona) ;
Leenders, William P. J. (Radboud Institute for Molecular Life Sciences) ;
Rosell, Rafael (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Montuenga, Luis M. (Universidad Pública de Navarra) ;
Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ;
Molina-Vila, Miguel Ángel (Quirón Dexeus University Hospital) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona)
We studied MET alterations in 474 advanced non-small-cell lung cancer (NSCLC) patients by nCounter, an RNA-based technique. We identified 3% with MET Δex14 mRNA and 3. 5% with very-high MET mRNA expression, a surrogate of MET amplification. [...]
2020 - 10.1002/1878-0261.12861
Molecular Oncology, Vol. 15 (december 2020) , p. 350-363
|
|
|
7.
|
|
13 p, 2.0 MB |
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
/
Garrido-Castro, Ana C. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Saura, Cristina (SOLTI Breast Cancer Research Group, Barcelona) ;
Barroso-Sousa, Romualdo (Present Address: Hospital Sírio-Libanês, Brasilia, Brazil) ;
Guo, Hao (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Data Sciences) ;
Ciruelos, Eva (Hospital Universitario 12 de Octubre (Madrid)) ;
Bermejo, Begoña (Centro de Investigación Biomédica en Red de Cáncer) ;
Gavilá, Joaquin (Fundació Institut Valencià d'Oncologia) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Paré Brunet, Laia (SOLTI Breast Cancer Research Group) ;
Céliz, Pamela (SOLTI Breast Cancer Research Group) ;
Villagrasa, Patricia (SOLTI Breast Cancer Research Group) ;
Li, Yisheng (The University of Texas MD Anderson Cancer Center. Department of Biostatistics, Division of Basic Sciences) ;
Savoie, Jennifer (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Xu, Zhan (Northern Arizona University. School of Communication) ;
Arteaga, Carlos L. (UT Southwestern Medical Center. Harold C. Simmons Comprehensive Cancer Center) ;
Krop, Ian E. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Solit, David B. (Memorial Sloan Kettering Cancer Center) ;
Mills, Gordon B. (The University of Texas MD Anderson Cancer Center. Present Address: Division of Basic Science Research, Department of Systems Biology) ;
Cantley, Lewis C. (Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College) ;
Winer, Eric P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Lin, Nancy U. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Rodon, Jordi (The University of Texas MD Anderson Cancer Center. Present Address: Department of Investigational Cancer Therapeutics) ;
Universitat Autònoma de Barcelona
Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. [...]
2020 - 10.1186/s13058-020-01354-y
Breast cancer research, Vol. 22 (november 2020)
|
|
|
8.
|
|
14 p, 572.1 KB |
Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer
/
Frigola Rissech, Joan (Vall d'Hebron Institut d'Oncologia) ;
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Carbonell, Caterina (Vall d'Hebron Institut d'Oncologia) ;
Callejo, Anna (Vall d'Hebron Institut d'Oncologia) ;
Iranzo, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
Pardo, Nuria (Vall d'Hebron Institut d'Oncologia) ;
Saoudi-Gonzalez, Nadia (Vall d'Hebron Institut d'Oncologia) ;
Martinez, Débora (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Jiménez, José (Vall d'Hebron Institut d'Oncologia) ;
Sansano, Irene (Hospital Universitari Vall d'Hebron) ;
Mancuso, Francesco M. (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Montuenga, Luis M. (Instituto de Investigación Sanitaria de Navarra) ;
Sanchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Amat, Ramón (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Immunotherapy has transformed advanced non-small cell lung cancer (NSCLC) treatment strategies and has led to unprecedented long-lasting responses in some patients. However, the molecular determinants driving these long-term responses remain elusive. [...]
2020 - 10.1002/1878-0261.12891
Molecular Oncology, 2020
|
|
|
9.
|
|
13 p, 6.8 MB |
Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity
/
Prat, Aleix (Vall d'Hebron Institut d'Oncologia) ;
Adamo, Barbara (Vall d'Hebron Institut d'Oncologia) ;
Fan, Cheng (Lineberger Comprehensive Cancer Center, University of North Carolina) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Vidal Losada, Maria (Vall d'Hebron Institut d'Oncologia) ;
Galván, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Palmer, Héctor G. ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Dawood, Shaheenah (Department of Medical Oncology, Dubai Hospital) ;
Rodón, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron) ;
Campo, Josep Maria Del (Vall d'Hebron Institut d'Oncologia) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
To improve our understanding of the biological relationships among different types of cancer, we have characterized variation in gene expression patterns in a set of 1,707 samples representing 6 human cancer types (breast, ovarian, brain, colorectal, lung adenocarcinoma and squamous cell lung cancer). [...]
2013 - 10.1038/srep03544
Scientific reports, Vol. 3 (december 2013)
|
|
|
10.
|
|
10 p, 1.9 MB |
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
/
Codony-Servat, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cuatrecasas, Miriam ;
Asensio, Elena (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Montironi, Carla (Hospital Clínic i Provincial de Barcelona) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Marín Aguilera, Mercedes (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Horndler, Carlos (Hospital Universitario Miguel Servet (Saragossa)) ;
Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rubini, Michele (Department of Experimental and Diagnostic Medicine, University of Ferrara) ;
Jares, Pedro (Hospital Clínic i Provincial de Barcelona) ;
Reig, Oscar (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Victoria, Iván (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gaba, Lydia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Martín Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ;
Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Fernández-Martos, Carlos (Fundació Institut Valencià d'Oncologia) ;
Feliu, Jaime (Centro de Investigación Biomédica en Red de Cáncer) ;
Méndez, Jose Carlos (Centro Oncológico de Galicia) ;
Méndez, Miguel (Hospital Universitario de Móstoles (Madrid)) ;
Gallego, Javier (Hospital General Universitario de Elche) ;
Salud, Antonieta (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Rojo, Federico (Pathology Department, Fundación Jiménez Diaz University) ;
Castells, Antoni (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
García-Albéniz, Xabier (Harvard T.H. Chan School of Public Health (Boston, Estats Units d'Amèrica)) ;
Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Universitat Autònoma de Barcelona
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. [...]
2017 - 10.1038/bjc.2017.279
British Journal of Cancer, Vol. 117 (november 2017) , p. 1777-1786
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
